» Articles » PMID: 38031118

DNA Methylation and Histone Post-translational Modifications in Atherosclerosis and a Novel Perspective for Epigenetic Therapy

Overview
Publisher Biomed Central
Date 2023 Nov 29
PMID 38031118
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerosis, which is a vascular pathology characterized by inflammation and plaque build-up within arterial vessel walls, acts as the important cause of most cardiovascular diseases. Except for a lipid-depository and chronic inflammatory, increasing evidences propose that epigenetic modifications are increasingly associated with atherosclerosis and are of interest from both therapeutic and biomarker perspectives. The chronic progressive nature of atherosclerosis has highlighted atherosclerosis heterogeneity and the fact that specific cell types in the complex milieu of the plaque are, by far, not the only initiators and drivers of atherosclerosis. Instead, the ubiquitous effects of cell type are tightly controlled and directed by the epigenetic signature, which, in turn, is affected by many proatherogenic stimuli, including low-density lipoprotein, proinflammatory, and physical forces of blood circulation. In this review, we summarize the role of DNA methylation and histone post-translational modifications in atherosclerosis. The future research directions and potential therapy for the management of atherosclerosis are also discussed. Video Abstract.

Citing Articles

Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions.

Sabit H, Arneth B, Altrawy A, Ghazy A, Abdelazeem R, Adel A Biomedicines. 2025; 13(2).

PMID: 40002898 PMC: 11852909. DOI: 10.3390/biomedicines13020485.


New insights into the structure domain and function of NLR family CARD domain containing 5.

Zhu H, Xiao C, Chen J, Guo B, Wang W, Tang Z Cell Commun Signal. 2025; 23(1):42.

PMID: 39849460 PMC: 11755879. DOI: 10.1186/s12964-024-02012-y.


Screening of m6A-associated ferroptosis-related genes in atherosclerosis based on WGCNA.

Jiang M, Zhao W, Wu L, Zhu G Front Cardiovasc Med. 2024; 11:1469805.

PMID: 39529974 PMC: 11550986. DOI: 10.3389/fcvm.2024.1469805.


Vascular medicine in the 21 century: Embracing comprehensive vasculature evaluation and multidisciplinary treatment.

Chaiter Y, Fink D, Machluf Y World J Clin Cases. 2024; 12(27):6032-6044.

PMID: 39328850 PMC: 11326099. DOI: 10.12998/wjcc.v12.i27.6032.


Epigenetics of hypertension as a risk factor for the development of coronary artery disease in type 2 diabetes mellitus.

Karabaeva R, Vochshenkova T, Mussin N, Albayev R, Kaliyev A, Tamadon A Front Endocrinol (Lausanne). 2024; 15:1365738.

PMID: 38836231 PMC: 11148232. DOI: 10.3389/fendo.2024.1365738.


References
1.
de Mendoza A, Nguyen T, Ford E, Poppe D, Buckberry S, Pflueger J . Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability. Genome Biol. 2022; 23(1):163. PMC: 9316731. DOI: 10.1186/s13059-022-02728-5. View

2.
Balakrishnan A, Guruprasad K, Satyamoorthy K, Joshi M . Interleukin-6 determines protein stabilization of DNA methyltransferases and alters DNA promoter methylation of genes associated with insulin signaling and angiogenesis. Lab Invest. 2018; 98(9):1143-1158. DOI: 10.1038/s41374-018-0079-7. View

3.
Zheng X, Wu Z, Xu K, Qiu Y, Su X, Zhang Z . Interfering histone deacetylase 4 inhibits the proliferation of vascular smooth muscle cells via regulating MEG3/miR-125a-5p/IRF1. Cell Adh Migr. 2018; 13(1):41-49. PMC: 6527374. DOI: 10.1080/19336918.2018.1506653. View

4.
Zhang Y, Mei J, Li J, Zhang Y, Zhou Q, Xu F . DNA Methylation in Atherosclerosis: A New Perspective. Evid Based Complement Alternat Med. 2021; 2021:6623657. PMC: 8249120. DOI: 10.1155/2021/6623657. View

5.
Xiao L, Cao Y, Wang Y, Lai X, Gao K, Du P . Aberrant histone modifications of global histone and promoter in CD14 monocytes from patients with coronary artery disease. Pharmazie. 2018; 73(4):202-206. DOI: 10.1691/ph.2018.7342. View